论文部分内容阅读
目的:探讨阿莫西林克拉维酸钾与哌拉西林舒巴坦钠联合阿奇霉素治疗小儿支原体肺炎中的临床疗效。方法:选取罗定市妇幼保健院2011年6月至2013年6月收治的210例支原体肺炎患儿,随机分为观察组105例予以阿莫西林克拉维酸钾与哌拉西林舒巴坦钠联用阿奇霉素治疗,对照组105例予以阿奇霉素治疗。疗程均为2周,比较两组患者疗效。结果:观察组总有效率92.4%(97/105);对照组总有效率78.1%(82/105),差异具有统计学意义(P<0.05);观察组平均退热时间(2.54±1.2)d明显低于对照组(3.7±2.4)d,差异具有统计学意义(P<0.05);平均止咳时间(5.8±1.4)d明显低于对照组(6.8±3.4)d,差异具有统计学意义(P<0.05)。观察组不良反应发生率12.4%(13/105),对照组不良反应发生率10.5%(11/105),差异无统计学意义(P>0.05)。结论:阿莫西林克拉维酸钾与哌拉西林舒巴坦治钠联合阿奇霉素治疗小儿支原体肺炎可较快改善临床症状,疗效果优于单用阿奇霉素序贯疗法,且不良反应无明显增加。
Objective: To investigate the clinical efficacy of amoxicillin-clavulanate and piperacillin-sulbactam combined with azithromycin in the treatment of mycoplasma pneumonia in children. Methods: A total of 210 children with mycoplasma pneumonia admitted from June 2011 to June 2013 in Luoding Maternal and Child Health Hospital were randomly divided into observation group (n = 105) and amoxicillin potassium clavulanate and piperacillin-sulbactam sodium In combination with azithromycin, 105 patients in the control group were treated with azithromycin. The course of treatment was 2 weeks, the curative effect of two groups was compared. Results: The total effective rate in the observation group was 92.4% (97/105); the total effective rate in the control group was 78.1% (82/105), the difference was statistically significant (P <0.05); the mean cooling time in the observation group was 2.54 ± 1.2 d was significantly lower than that of the control group (3.7 ± 2.4) d, the difference was statistically significant (P <0.05); the average cough time was 5.8 ± 1.4 d was significantly lower than the control group (6.8 ± 3.4) d, the difference was statistically significant (P <0.05). The incidence of adverse reactions in the observation group was 12.4% (13/105), while the incidence of adverse reactions in the control group was 10.5% (11/105), with no significant difference (P> 0.05). Conclusion: Amoxicillin and clarithromycin sodium sulbactam combined with azithromycin in children with mycoplasma pneumonia can quickly improve the clinical symptoms, the effect is better than the single azithromycin sequential therapy, and no significant increase in adverse reactions.